NCT04270942: A reported trial by Provention Bio, a Sanofi Company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04270942 |
|---|---|
| Title | An Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop Type 1 Diabetes |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 26, 2020 |
| Completion date | Jan. 22, 2024 |
| Required reporting date | Jan. 21, 2025, midnight |
| Actual reporting date | Jan. 20, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |